Aslan Pharmaceuticals makes appointments to scientific board


Dr Melinda Gooderham, Dr Jacob Thyssen and Associate Professor Peter Foley will all join the company’s scientific advisory board

Aslan Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, has announced the appointments of Dr Melinda Jennifer Gooderham, MSc MD FRCPC, Dr Jacob Thyssen, MD PhD DmSci, and Associate Professor Peter Foley, BMedSci MBBS MD FACD, as members of its scientific advisory board (SAB).

The SAB, chaired by Dr Lawrence Eichenfield, MD FAAD, was established in September following the appointment of Dr Eichenfield and Dr Eric Simpson, MD MCR. It comprises researchers with experience in allergic and inflammatory disease who will play a role in advancing the company’s clinical development pipeline, strategy and R&D activities.

Dr Melinda Gooderham is the Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research, Ontario, Canada. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre.

Dr Jacob Thyssen is Chief Consultant with the Department of Dermatology at Bispebjerg Hospital, Denmark and serves as a Director of several organisations including the International Eczema Council, the European Task Force of Atopic Dermatitis.

Associate Professor Peter Foley is Head, Dermatology Research, Department of Dermatology at St Vincent’s Hospital, Melbourne. As Australia’s only councillor on the International Psoriasis Council, Professor Foley has served as co-convener for various societies, including the Australasian Psoriasis Registry and Australian Psoriasis Treatment Goals.

Sign up for your free email newsletter

Dr Lawrence Eichenfield, Chair of Aslan’s Scientific Advisory Board, said: “Each new Board addition brings valuable insight, global perspective and a deep understanding of this burdensome inflammatory disease that will be instrumental in the development of ASLAN004 as a potentially novel, differentiated treatment option for atopic dermatitis patients. I’m excited to be working together to help realize ASLAN’s vision of meeting the pressing needs of these patients.”